1358 related articles for article (PubMed ID: 17957277)
1. Molecular pathology and pharmacogenomics in Alzheimer's disease: polygenic-related effects of multifactorial treatments on cognition, anxiety and depression.
Cacabelos R
Methods Find Exp Clin Pharmacol; 2007 Jul; 29 Suppl A():1-91. PubMed ID: 17957277
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenomics in Alzheimer's disease.
Cacabelos R
Methods Mol Biol; 2008; 448():213-357. PubMed ID: 18370236
[TBL] [Abstract][Full Text] [Related]
3. Influence of pharmacogenetic factors on Alzheimer's disease therapeutics.
Cacabelos R
Neurodegener Dis; 2008; 5(3-4):176-8. PubMed ID: 18322383
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenomics and therapeutic strategies for dementia.
Cacabelos R
Expert Rev Mol Diagn; 2009 Sep; 9(6):567-611. PubMed ID: 19732004
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenomics and therapeutic prospects in dementia.
Cacabelos R
Eur Arch Psychiatry Clin Neurosci; 2008 Mar; 258 Suppl 1():28-47. PubMed ID: 18344047
[TBL] [Abstract][Full Text] [Related]
6. Genomics and phenotypic profiles in dementia: implications for pharmacological treatment.
Cacabelos R; Fernández-Novoa L; Corzo L; Pichel V; Lombardi V; Kubota Y
Methods Find Exp Clin Pharmacol; 2004; 26(6):421-44. PubMed ID: 15349138
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenomics and therapeutic prospects in Alzheimer's disease.
Cacabelos R
Expert Opin Pharmacother; 2005 Oct; 6(12):1967-87. PubMed ID: 16197352
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetic basis for therapeutic optimization in Alzheimer's disease.
Cacabelos R
Mol Diagn Ther; 2007; 11(6):385-405. PubMed ID: 18078356
[TBL] [Abstract][Full Text] [Related]
9. The application of functional genomics to Alzheimer's disease.
Cacabelos R
Pharmacogenomics; 2003 Sep; 4(5):597-621. PubMed ID: 12943467
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenomics of Alzheimer's disease: novel therapeutic strategies for drug development.
Cacabelos R; Cacabelos P; Torrellas C; Tellado I; Carril JC
Methods Mol Biol; 2014; 1175():323-556. PubMed ID: 25150875
[TBL] [Abstract][Full Text] [Related]
11. Molecular genetics of Alzheimer's disease and aging.
Cacabelos R; Fernandez-Novoa L; Lombardi V; Kubota Y; Takeda M
Methods Find Exp Clin Pharmacol; 2005 Jul; 27 Suppl A():1-573. PubMed ID: 16470248
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenomics for the treatment of dementia.
Cacabelos R
Ann Med; 2002; 34(5):357-79. PubMed ID: 12452480
[TBL] [Abstract][Full Text] [Related]
13. Alzheimer's disease pathogenesis and therapeutic interventions.
Parihar MS; Hemnani T
J Clin Neurosci; 2004 Jun; 11(5):456-67. PubMed ID: 15177383
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenomic protocols in CNS disorders and dementia.
Cacabelos R
Neurodegener Dis; 2010; 7(1-3):167-9. PubMed ID: 20197699
[TBL] [Abstract][Full Text] [Related]
15. Complex disease-associated pharmacogenetics: drug efficacy, drug safety, and confirmation of a pathogenetic hypothesis (Alzheimer's disease).
Roses AD; Saunders AM; Huang Y; Strum J; Weisgraber KH; Mahley RW
Pharmacogenomics J; 2007 Feb; 7(1):10-28. PubMed ID: 16770341
[TBL] [Abstract][Full Text] [Related]
16. [Therapy of Alzheimer disease].
Kovács T
Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenetic aspects of therapy with cholinesterase inhibitors: the role of CYP2D6 in Alzheimer's disease pharmacogenetics.
Cacabelos R; Llovo R; Fraile C; Fernández-Novoa L
Curr Alzheimer Res; 2007 Sep; 4(4):479-500. PubMed ID: 17908053
[TBL] [Abstract][Full Text] [Related]
18. Genomic characterization of Alzheimer's disease and genotype-related phenotypic analysis of biological markers in dementia.
Cacabelos R
Pharmacogenomics; 2004 Dec; 5(8):1049-105. PubMed ID: 15584876
[TBL] [Abstract][Full Text] [Related]
19. Involvement of paraoxonase 1 genetic variants in Alzheimer's disease neuropathology.
Leduc V; Théroux L; Dea D; Robitaille Y; Poirier J
Eur J Neurosci; 2009 Nov; 30(9):1823-30. PubMed ID: 19863653
[TBL] [Abstract][Full Text] [Related]
20. ApoE genotype accounts for the vast majority of AD risk and AD pathology.
Raber J; Huang Y; Ashford JW
Neurobiol Aging; 2004; 25(5):641-50. PubMed ID: 15172743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
